MP-1, Inc. Changes Name to Phoenix Biosciences, Inc. to Reflect Company Growth.
HOLLYWOOD, Fla. -- Phoenix Biosciences, Inc. strengthens its commitment to developing treatments for HIV/AIDS HIV/AIDS Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
Phoenix Biosciences, Inc., focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS, announced today that it has officially changed its name from MP-1, Inc. to Phoenix Biosciences, Inc. This reflects the company's growth and its continued focus on testing its compound drug PBS PBS
in full Public Broadcasting Service
Private, nonprofit U.S. corporation of public television stations. PBS provides its member stations, which are supported by public funds and private contributions rather than by commercials, with educational, cultural, 119, which was developed as a unique approach for treating HIV/AIDS.
PBS119 takes a different approach than the current drugs used to treat HIV/AIDS. Instead of attacking the virus itself, this treatment uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. In preliminary pilot tests conducted by Phoenix Biosciences, PBS119 demonstrated positive results, which provided the company with the added assurance to continue with their unique approach.
"With an increased focus on HIV/AIDS, our new name Phoenix Biosciences represents a turning point for the company," said Dr. Robert Keller, Chairman, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and CSO (Chief Security Officer) The person in charge of all staff members who are responsible for promulgating, enforcing and administering security policies for all systems within an enterprise or division. of Phoenix Biosciences. "An estimated 40 million people are infected with HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and we are committed to accelerating the process allowing us to offer a new, affordable and non-toxic treatment for HIV."
Phoenix is currently in the process of raising funds in order to conduct clinical trials. The company is determined to complete these clinical trials and gain FDA FDA
Food and Drug Administration
n.pr See Food and Drug Administration.
n.pr the abbreviation for the Food and Drug Administration. approval to begin offering patients this treatment worldwide.
About Phoenix Biosciences, Inc.
Phoenix Biosciences, Inc. is focused on developing, testing and offering affordable treatments for immune dysfunctions, with a concentration on HIV/AIDS in the last decade. The company has developed the compound drug PBS119 as a different approach for treating the HIV virus. This approach uses the patient's own immune system to create an unacceptable environment for the virus inside the cell. With headquarters in Hollywood, Florida, Phoenix Biosciences, Inc. is a privately-held biotech company owned by parent company Immune Balance Technologies, LLC (Logical Link Control) See "LANs" under data link protocol.
LLC - Logical Link Control (IBT (1) (Instructor Based Training) Training courses conducted by human teachers.
(2) (Internet Based Training) Training courses provided via the Internet. ). In addition, IBT owns Vit-Immune, which develops, tests and markets nutritional supplements that assist in the general well-being of people and enhances the benefits of PBS119 for those suffering from chronic immune diseases including HIV/AIDS. For more information about Phoenix Biosciences, Inc. or Vit-Immune, please email email@example.com or visit www.robkellermd.org